{
    "address1": "Lilly Corporate Center",
    "city": "Indianapolis",
    "state": "IN",
    "zip": "46285",
    "country": "United States",
    "phone": "317 276 2000",
    "website": "https://www.lilly.com",
    "industry": "Drug Manufacturers\u2014General",
    "industryDisp": "Drug Manufacturers\u2014General",
    "sector": "Healthcare",
    "sectorDisp": "Healthcare",
    "longBusinessSummary": "Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.",
    "fullTimeEmployees": 39000,
    "companyOfficers": [
        {
            "maxAge": 1,
            "name": "Mr. David A. Ricks",
            "age": 54,
            "title": "Chairman, CEO & Pres",
            "yearBorn": 1968,
            "fiscalYear": 2022,
            "totalPay": 4416885,
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Ms. Anat  Ashkenazi",
            "age": 49,
            "title": "Exec. VP & CFO",
            "yearBorn": 1973,
            "fiscalYear": 2022,
            "totalPay": 2125270,
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Dr. Daniel M. Skovronsky M.D., Ph.D.",
            "age": 48,
            "title": "Exec. VP, Chief Scientific & Medical Officer and Pres of Lilly Research Laboratories",
            "yearBorn": 1974,
            "fiscalYear": 2022,
            "totalPay": 2716346,
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Ms. Anat  Hakim J.D.",
            "age": 53,
            "title": "Exec. VP, Gen. Counsel & Sec.",
            "yearBorn": 1969,
            "fiscalYear": 2022,
            "totalPay": 1979674,
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Mr. Patrik  Jonsson",
            "age": 55,
            "title": "EVP, Chief Customer Officer, Pres of Lilly USA & Lilly Immunology",
            "yearBorn": 1967,
            "fiscalYear": 2022,
            "totalPay": 1673270,
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Mr. Donald A. Zakrowski",
            "title": "Chief Accounting Officer & VP of Fin.",
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Mr. Diogo  Rau",
            "title": "EVP & Chief Information and Digital Officer",
            "fiscalYear": 2021,
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Mr. Alonzo  Weems",
            "age": 51,
            "title": "EVP of Enterprise Risk Management and Chief Ethics & Compliance Officer",
            "yearBorn": 1971,
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Ms. Leigh Ann Pusey",
            "age": 59,
            "title": "Exec. VP of Corp. Affairs & Communications",
            "yearBorn": 1963,
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Mr. Eric  Dozier",
            "age": 55,
            "title": "Exec. VP of HR & Diversity",
            "yearBorn": 1967,
            "exercisedValue": 0,
            "unexercisedValue": 0
        }
    ],
    "auditRisk": 3,
    "boardRisk": 5,
    "compensationRisk": 1,
    "shareHolderRightsRisk": 9,
    "overallRisk": 5,
    "governanceEpochDate": 1693526400,
    "compensationAsOfEpochDate": 1672444800,
    "maxAge": 86400,
    "priceHint": 2,
    "previousClose": 573.23,
    "open": 572.33,
    "dayLow": 571.22,
    "dayHigh": 587.55,
    "regularMarketPreviousClose": 573.23,
    "regularMarketOpen": 572.33,
    "regularMarketDayLow": 571.22,
    "regularMarketDayHigh": 587.55,
    "dividendRate": 4.52,
    "dividendYield": 0.0077,
    "exDividendDate": 1691971200,
    "payoutRatio": 0.5877,
    "fiveYearAvgDividendYield": 1.59,
    "beta": 0.315006,
    "trailingPE": 82.02238,
    "forwardPE": 46.397152,
    "volume": 4311028,
    "regularMarketVolume": 4311028,
    "averageVolume": 2804435,
    "averageVolume10days": 2488390,
    "averageDailyVolume10Day": 2488390,
    "bid": 0.0,
    "ask": 0.0,
    "bidSize": 800,
    "askSize": 1000,
    "marketCap": 556723535872,
    "fiftyTwoWeekLow": 296.32,
    "fiftyTwoWeekHigh": 587.55,
    "priceToSalesTrailing12Months": 18.862074,
    "fiftyDayAverage": 497.7158,
    "twoHundredDayAverage": 405.4585,
    "trailingAnnualDividendRate": 4.22,
    "trailingAnnualDividendYield": 0.007361792,
    "currency": "USD",
    "enterpriseValue": 543498338304,
    "profitMargins": 0.22014,
    "floatShares": 897487590,
    "sharesOutstanding": 949294976,
    "sharesShort": 5185112,
    "sharesShortPriorMonth": 5139181,
    "sharesShortPreviousMonthDate": 1689292800,
    "dateShortInterest": 1692057600,
    "sharesPercentSharesOut": 0.0055,
    "heldPercentInsiders": 0.00153,
    "heldPercentInstitutions": 0.83985,
    "shortRatio": 1.68,
    "shortPercentOfFloat": 0.0064999997,
    "impliedSharesOutstanding": 949294976,
    "bookValue": 12.303,
    "priceToBook": 47.66805,
    "lastFiscalYearEnd": 1672444800,
    "nextFiscalYearEnd": 1703980800,
    "mostRecentQuarter": 1688083200,
    "earningsQuarterlyGrowth": 0.851,
    "netIncomeToCommon": 6497500160,
    "trailingEps": 7.15,
    "forwardEps": 12.64,
    "pegRatio": 2.36,
    "lastSplitFactor": "2:1",
    "lastSplitDate": 876960000,
    "enterpriseToRevenue": 18.414,
    "enterpriseToEbitda": 55.658,
    "52WeekChange": 0.8604784,
    "SandP52WeekChange": 0.08443928,
    "lastDividendValue": 1.13,
    "lastDividendDate": 1691971200,
    "exchange": "NYQ",
    "quoteType": "EQUITY",
    "symbol": "LLY",
    "underlyingSymbol": "LLY",
    "shortName": "Eli Lilly and Company",
    "longName": "Eli Lilly and Company",
    "firstTradeDateEpochUtc": 76253400,
    "timeZoneFullName": "America/New_York",
    "timeZoneShortName": "EDT",
    "uuid": "7b37be39-dfde-3602-b0e4-4d76cf52143b",
    "messageBoardId": "finmb_285467",
    "gmtOffSetMilliseconds": -14400000,
    "currentPrice": 586.46,
    "targetHighPrice": 640.0,
    "targetLowPrice": 340.0,
    "targetMeanPrice": 559.87,
    "targetMedianPrice": 597.5,
    "recommendationMean": 1.9,
    "recommendationKey": "buy",
    "numberOfAnalystOpinions": 26,
    "totalCash": 2941299968,
    "totalCashPerShare": 3.271,
    "ebitda": 9765000192,
    "totalDebt": 18953500672,
    "quickRatio": 0.633,
    "currentRatio": 1.128,
    "totalRevenue": 29515499520,
    "debtToEquity": 169.997,
    "revenuePerShare": 32.763,
    "returnOnAssets": 0.10182,
    "returnOnEquity": 0.65602994,
    "grossProfits": 21911600000,
    "freeCashflow": 5056487424,
    "operatingCashflow": 5740599808,
    "earningsGrowth": 0.857,
    "revenueGrowth": 0.281,
    "grossMargins": 0.77769995,
    "ebitdaMargins": 0.33084,
    "operatingMargins": 0.28116,
    "financialCurrency": "USD",
    "trailingPegRatio": 1.5459,
    "parent_etfs": [
        "AGNG"
    ]
}